Yoshinori Uchihara

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK-Aberrant Neuroblastoma.

Feasibility and Efficacy of Lorlatinib in Japanese Patients With Relapsed/Refractory ALK-Aberrant Neuroblastoma.

Journal: Pediatric blood & cancer
Published: May 07, 2026

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Journal: Pediatric blood & cancer
Published: April 30, 2026

Stepwise malignant transformation from MHL to UESL via activation of C19MC and loss of TP53.

Stepwise malignant transformation from MHL to UESL via activation of C19MC and loss of TP53.

Journal: NPJ precision oncology
Published: February 14, 2026

Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: Cancer medicine
Published: August 01, 2025

Clinical challenges of cancer predisposition syndromes with pediatric central nervous system tumors: a single-center study.

Clinical challenges of cancer predisposition syndromes with pediatric central nervous system tumors: a single-center study.

Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Published: May 26, 2025

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

Journal: Cell reports. Medicine
Published: April 18, 2025

Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.

Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.

Journal: Blood
Published: September 03, 2024

Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with KMT2A rearrangement.

Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with KMT2A rearrangement.

Journal: Nature communications
Published: July 10, 2024

MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.

MGMT protein expression is a reliable predictive biomarker for temozolomide-containing chemotherapy in osteosarcoma.

Journal: Cancer science
Published: June 04, 2024

Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura.

Successful sequential therapy with rituximab and daratumumab for refractory posttransplant immune thrombocytopenic purpura.

Journal: Pediatric blood & cancer
Published: April 27, 2023

High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.

High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.

Journal: Pediatric blood & cancer
Published: December 11, 2022

Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.

Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.

Journal: Pediatric blood & cancer
Published: November 17, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026